Literature DB >> 3041218

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

S Rodenhuis, M L van de Wetering, W J Mooi, S G Evers, N van Zandwijk, J L Bos.   

Abstract

To define the role of cellular oncogenes in human cancers, we studied the prevalence of mutational activation of ras oncogenes in untreated non-small-cell lung cancer. Genomic DNA was extracted from 39 tumor specimens obtained by thoracotomy and was examined for activating point mutations in codons 12, 13, and 61 of the H-ras, K-ras, and N-ras genes. A novel, highly sensitive assay based on oligonucleotide hybridization following an in vitro amplification step was employed. The K-ras gene was found to be activated by point mutations in codon 12 in 5 of 10 adenocarcinomas. Two of these tumors were less than 2 cm in size and had not metastasized. No ras gene mutations were observed in 15 squamous-cell carcinomas, 10 large-cell carcinomas, 1 carcinoid, 2 metastatic adenocarcinomas from primary tumors outside the lung, and 1 small-cell carcinoma. An approximately 20-fold amplification of the unmutated K-ras gene was observed in a tumor that proved to be a solitary lung metastasis of a rectal carcinoma. We conclude that mutational K-ras activation may be an important early event in the pathogenesis of adenocarcinoma of the lung but that amplification of ras genes or mutational activation of H-ras or N-ras does not play a major part in non-small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3041218     DOI: 10.1056/NEJM198710083171504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  147 in total

Review 1.  Molecular biology and respiratory disease. 4. Cancer genes.

Authors:  K Sikora; G Ong
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

Review 2.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

3.  Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.

Authors:  Hua Wang; Matthew B Schabath; Ying Liu; Olya Stringfield; Yoganand Balagurunathan; John J Heine; Steven A Eschrich; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2015-11-12       Impact factor: 4.785

4.  Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study.

Authors:  Frederica P Perera; Deliang Tang; Paul Brandt-Rauf; Regina M Santella; La Verne A Mooney; Yi-Hsuan Tu; Ivona Bendkowska; Douglas A Bell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

5.  Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Authors:  Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

6.  Structure of the 1,4-Bis(2'-deoxyadenosin-N(6)-yl)-2S,3S-butanediol intrastrand DNA cross-link arising from butadiene diepoxide in the human N-ras codon 61 sequence.

Authors:  Wen Xu; W Keither Merritt; Lubomir V Nechev; Thomas M Harris; Constance M Harris; R Stephen Lloyd; Michael P Stone
Journal:  Chem Res Toxicol       Date:  2007-01-27       Impact factor: 3.739

7.  Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.

Authors:  L A Doyle; M Mabry; R A Stahel; R Waibel; L H Goldstein
Journal:  Br J Cancer Suppl       Date:  1991-06

8.  Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction.

Authors:  Y Suzuki; G Tamura; C Maesawa; T Fujioka; T Kubo; R Satodate
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

Authors:  Takuya Araki; Kimihiro Shimizu; Katsunori Nakamura; Tomonori Nakamura; Yasumasa Mitani; Kyoko Obayashi; Yukiyoshi Fujita; Seiichi Kakegawa; Yohei Miyamae; Kyoichi Kaira; Takefumi Ishidao; Alexander Lezhava; Yoshihide Hayashizaki; Izumi Takeyoshi; Koujirou Yamamoto
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

10.  Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance.

Authors:  J Lorenz; T Friedberg; R Paulus; F Oesch; R Ferlinz
Journal:  Clin Investig       Date:  1994-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.